Frequency of intervention‐related ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments
1 finding from 1 review
Frequency of intervention‐related non‐ocular adverse events ( · people with primary macula‐involving rhegmatogenous retinal detachments
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants reporting an adverse event · children under the age of 18 with cerebral palsy (GMFCS levels III to V)
1 finding from 1 review
Adverse events: number of adverse events Active intervention: 12 months · adults and children with cystic fibrosis
1 finding from 1 review
Safety of the intervention (adverse effects) · non‐small cell lung cancer
1 finding from 1 review
Adverse events associated with treatment · patients older than 8 years with peritonsillar abscess
1 finding from 1 review
Minor adverse events assessed: related to intervention only (e.g. redness) · COPD
1 finding from 1 review
Minor adverse events assessed: related to intervention only (e.g. redness) · COPD
NMES showed no clear difference in minor adverse events assessed: related to intervention only (e.g.… compared with usual care (with or without sham NMES) (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in adverse events leading to withdrawal: intermediate‐term duration of… compared with mizolastine 10 mg (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with chronic spontaneous urticaria
Loratadine 10 mg showed no clear difference in adverse events leading to withdrawal: intermediate‐term duration of… compared with emedastine 2 mg (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with chronic spontaneous urticaria
Hydroxyzine 25 mg showed no clear difference in adverse events leading to withdrawal: intermediate‐term duration of… compared with placebo (low certainty).
1 finding from 1 review
Number experiencing adverse effects · chronic pain (excluding headache) in adults
1 finding from 1 review
Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) · Healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention IVR versus usual care · overweight or obese individuals (both children and adults)
1 finding from 1 review
Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye
1 finding from 1 review
Proportion of participants with intervention‐related, vision‐threatening adverse events at 1 to 4 weeks · people with dry eye
1 finding from 1 review
Proportion of participants with adverse events with a probable causal link with the study interventions at six months · adults
Summary of findings 1: blue‐light filtering lenses may leads to lower proportion of participants with adverse events with a probable… compared with non‐blue‐light filtering lenses (low certainty).
1 finding from 1 review
Intervention not reported
Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of participants experiencing 1 or more serious adverse events at the end of the intervention period · cognitively healthy people in late life
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse outcome: unintended adverse events attributable to the intervention ATCS Plus, IVR versus usual care · patients with diabetes mellitus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found